动物造模,SARS-CoV-2 z-bio 2021-11-06 371

　　Scientists from Texas Biomedical Company and Southwest National Primate Research Center (SNPRC) published their findings in a comprehensive animal model study of SARS-CoV-2 in natural microbiology.

　　The results of these findings were first published online on BioRxiv in June 2020. The study assessed the susceptibility of three non-human primates (NHPs) (Macaques from India, baboons from Africa and common mos monkeys of New World origin) to SARS-CoV-2 and the development of COVID-19 disease. During the research process, macaques and baboons have broad prospects as animal models for COVID-19 disease research. According to the results of the study, the researchers recommend using rhesus monkeys as a model for developing vaccines, but hihi shows a greater development trend and understanding the relationship between COVID-19 and diabetes has become a potential for evaluating antiviral treatments and comorbidities select. COVID-19 and heart disease. "The advantage of Texas Biomed's unique research model is that its expertise can support individual scientific research and commissioned research with campus animals, biosafety and regulatory capabilities, which is vital. It is very important for a wide range of research from discovery to discovery. It’s useful. From pre-clinical development to clinical trials,” explains Dr. Joan Turner, vice president of Texas Biomedical Research.

　　Animal models of infectious diseases (such as COVID-19) enable scientists around the world to determine whether candidate vaccines and antiviral therapies currently under development can be used as human interventions. In addition, animal models can help scientists understand the disease progression of people with weakened immune systems and help them develop treatments. Dr. Deepak Kaushall, Director of the Southwest National Primate Center, said: "Finding an animal model suitable for COVID-19 will allow us to quickly discover these important findings. This is an important step in the fight against this disease. Animal data, FDA has no detailed information yet. Vaccines and antiviral therapies are unlikely to be approved for use in humans. Even in animals currently undergoing human testing, animal model data show human diseases and potential treatments." A team of 43 researchers has been able to fully understand the clinical response of SARS-CoV-2 infection/COVID-19 disease, the virus and imaging examinations in these three NHPs, and we have reported immunology and histopathology (tissue School inspection) results.

　　The study finally found that the progress of SARS-CoV-2 infection in humans by non-human primates is similar. Some infected people are more sick than others, with signs of virus and pneumonia in the upper and lower respiratory tracts. Dr. Kaushal Kaushal explained: “Our results show that these animal models provide relevant and quantifiable information when we understand the diseases and treatments used in human clinical trials and vaccine targets.” In previous animal studies, Makaku is a viable model of SARS-CoV-2. This is the first time that researchers have conducted a longitudinal study of three different primate models. In addition, the researchers determined whether the virus was present in bronchoalveolar lavage (lung fluid collection) and nasal swabs, and performed chest X-rays and CT scans to assess lung health after infection, which is the most comprehensive assessment , I used this method.

　　The results showed that the macaque and baboon models formed strong signs of acute viral infection and caused pneumonia. However, the study found that the immune system of non-human primates responded strongly and eliminated the infection. Special bone marrow cells flow from the blood to the lungs and secrete high levels of type I interferons and cytokines. The appearance of these special phagocytes corresponds to the decline of virus and disease indicators. This study is also the first report on SARS-CoV-2 infection that specifically alters lung lymphoid cells (T cells). Rhesus monkeys produce a powerful and highly specific immune response that enables animals to clear the virus. This discovery helps primate models understand the immune response to SARS-CoV-2, and helps to develop interventions that can produce similar responses, as well as vaccines that require special treatments and efficacy. They have been shown to be useful for evaluation. safety.